In my opinion it is only to do with uncertainty around the news cycle and establishing Avita as an American company in the minds of investors there. None of the indications will go away, only the level of demand given lockdowns in relation to burns. All of the other chronic conditions simply require approvals, trial results and progress. Nothing has changed in the investment thesis around unmet needs, better patient outcomes and lower costs. I’m taking the view that it requires patience.
AVH on NASDAQ, page-382
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.81 |
Change
-0.150(3.79%) |
Mkt cap ! $270.4M | |||
| Open | High | Low | Value | Volume |
| $3.94 | $3.94 | $3.78 | $315.8K | 82.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 503 | $3.80 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.82 | 799 | 2 |
View Market Depth
| Last trade - 12.41pm 15/11/2024 (20 minute delay) ? |
| AVH (ASX) Chart |